Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.68 |
| ▸ | HPGD | P15428 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | APP | P05067 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26095496 | 1.00 | MAPT (0.68) | MAPTHPGDKMT2AALOX15MEN1 | |
| SCHEMBL31659862 | 1.00 | MAPT (0.68) | MAPTHPGDKMT2AALOX15MEN1 | |
| SCHEMBL15425083 | 0.87 | MAPT (0.59) | MAPTHPGDKMT2AALOX15MEN1 | |
| SCHEMBL17877992 | 0.87 | APP (0.61) | MAPTHPGDKMT2AALOX15MEN1 | |
| SCHEMBL560667 | 0.86 | APP (0.73) | MAPTHPGDKMT2AALOX15MEN1 | |
| Bromide SCHEMBL1660202 | 0.85 | APP (0.71) | MAPTHPGDKMT2AALOX15MEN1 | |
| SCHEMBL15425076 | 0.83 | APP (0.69) | MAPTHPGDKMT2AALOX15MEN1 | |
| SCHEMBL31660327 | 0.83 | MAPT (0.68) | MAPTHPGDKMT2AALOX15MEN1 | |
| SCHEMBL22890844 | 0.83 | APP (0.65) | MAPTHPGDKMT2AALOX15MEN1 | |
| SCHEMBL16500504 | 0.83 | APP (0.65) | MAPTHPGDKMT2AALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4173485-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-11180518-B2 | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-11-23 | — | — | US | disclosed |
| EP-2307381-B1 | NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2021-01-13 | — | — | EP | disclosed |
| EP-2687513-B1 | DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2020-12-02 | — | — | EP | disclosed |
| US-20200165279-A1 | PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-05-28 | — | — | US | disclosed |
| US-10435373-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2019-10-08 | — | — | US | disclosed |
| EP-2684873-B1 | DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2019-01-16 | — | — | EP | disclosed |
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2016-06-30 | — | — | US | disclosed |
| EP-2687513-A1 | Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases | Ludwig-Maximilians-Universität München (DE) | 2014-01-22 | — | — | EP | disclosed |
| EP-2684873-A1 | DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | Ludwig-Maximilians-Universität München (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2011-12-01 | — | — | US | disclosed |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2011-12-01 | — | — | US | disclosed |
| WO-2010000372-A2 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | PARK7, APP, HYPK | MAPT 8/4885HPGD 3050/4885KMT2A 4175/4885 |
| US-20200165279-A1 | PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA | TYR, MITF, VHL | MAPT 3145/4885HPGD 48/4885KMT2A 806/4885 |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | PARK7, HYPK, IK | MAPT 40/4885HPGD 4246/4885KMT2A 4170/4885 |
| US-11180518-B2 | Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma | TYR, MITF, VHL | MAPT 3145/4885HPGD 48/4885KMT2A 806/4885 |
| US-10435373-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | PARK7, APP, HYPK | MAPT 8/4885HPGD 3050/4885KMT2A 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.